Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial | Acute Coronary Syndromes | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Rudisch  B, Nemeroff  CB.  Epidemiology of comorbid coronary artery disease and depression.  Biol Psychiatry. 2003;54(3):227-240. doi:10.1016/S0006-3223(03)00587-0PubMedGoogle ScholarCrossref
Frasure-Smith  N, Lespérance  F, Talajic  M.  Depression following myocardial infarction: impact on 6-month survival.  JAMA. 1993;270(15):1819-1825. doi:10.1001/jama.1993.03510150053029PubMedGoogle ScholarCrossref
Lespérance  F, Frasure-Smith  N, Talajic  M, Bourassa  MG.  Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction.  Circulation. 2002;105(9):1049-1053. PubMedGoogle ScholarCrossref
Thombs  BD, de Jonge  P, Coyne  JC,  et al.  Depression screening and patient outcomes in cardiovascular care: a systematic review.  JAMA. 2008;300(18):2161-2171. doi:10.1001/jama.2008.667PubMedGoogle ScholarCrossref
Pizzi  C, Rutjes  AW, Costa  GM,  et al.  Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease.  Am J Cardiol. 2011;107(7):972-979. PubMedGoogle ScholarCrossref
Glassman  AH, O’Connor  CM, Califf  RM,  et al; Sertraline Antidepressant Heart Attack Randomized Trial Group.  Sertraline treatment of major depression in patients with acute MI or unstable angina.  JAMA. 2002;288(6):701-709. doi:10.1001/jama.288.6.701PubMedGoogle ScholarCrossref
Honig  A, Kuyper  AM, Schene  AH,  et al; MIND-IT Investigators.  Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.  Psychosom Med. 2007;69(7):606-613. PubMedGoogle ScholarCrossref
Lespérance  F, Frasure-Smith  N, Koszycki  D,  et al.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.  JAMA. 2007;297(4):367-379. doi:10.1001/jama.297.4.367PubMedGoogle ScholarCrossref
Kim  JM, Bae  KY, Stewart  R,  et al.  Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.  J Clin Psychiatry. 2015;76(1):62-68. doi:10.4088/JCP.14m09281PubMedGoogle ScholarCrossref
van Melle  JP, de Jonge  P, Honig  A,  et al; MIND-IT Investigators.  Effects of antidepressant treatment following myocardial infarction.  Br J Psychiatry. 2007;190(6):460-466. doi:10.1192/bjp.bp.106.028647PubMedGoogle ScholarCrossref
Glassman  AH, Bigger  JT  Jr, Gaffney  M.  Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants.  Arch Gen Psychiatry. 2009;66(9):1022-1029. doi:10.1001/archgenpsychiatry.2009.121PubMedGoogle ScholarCrossref
Berkman  LF, Blumenthal  J, Burg  M,  et al.  Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial.  JAMA. 2003;289(23):3106-3116. doi:10.1001/jama.289.23.3106PubMedGoogle ScholarCrossref
Taylor  CB, Youngblood  ME, Catellier  D,  et al; ENRICHD Investigators.  Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.  Arch Gen Psychiatry. 2005;62(7):792-798. doi:10.1001/archpsyc.62.7.792PubMedGoogle ScholarCrossref
Rieckmann  N, Kronish  IM, Shapiro  PA, Whang  W, Davidson  KW.  Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study.  JAMA Intern Med. 2013;173(12):1150-1151. doi:10.1001/jamainternmed.2013.910PubMedGoogle ScholarCrossref
Kim  JM, Stewart  R, Bae  KY,  et al.  Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study.  Psychol Med. 2015;45(8):1641-1652. PubMedGoogle ScholarCrossref
Lee  KH, Jeong  MH, Kim  HM,  et al; Korea Acute Myocardial Infarction Registry Investigators.  Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.  J Am Coll Cardiol. 2011;58(16):1664-1671. doi:10.1016/j.jacc.2011.05.057PubMedGoogle ScholarCrossref
Lee  JM, Rhee  TM, Hahn  JY,  et al; KAMIR Investigators.  Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock.  J Am Coll Cardiol. 2018;71(8):844-856. doi:10.1016/j.jacc.2017.12.028PubMedGoogle ScholarCrossref
Kim  JH, Chae  SC, Oh  DJ,  et al; Korea Acute Myocardial Infarction–National Institutes of Health Registry Investigators.  Multicenter cohort study of acute myocardial infarction in Korea.  Circ J. 2016;80(6):1427-1436. doi:10.1253/circj.CJ-16-0061PubMedGoogle ScholarCrossref
Anderson  JL, Adams  CD, Antman  EM,  et al.  2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction.  J Am Coll Cardiol. 2013;61(23):e179-e347. PubMedGoogle ScholarCrossref
Beck  AT, Ward  CH, Mendelson  M, Mock  J, Erbaugh  J.  An inventory for measuring depression.  Arch Gen Psychiatry. 1961;4(6):561-571. doi:10.1001/archpsyc.1961.01710120031004PubMedGoogle ScholarCrossref
Sheehan  DV, Lecrubier  Y, Sheehan  KH,  et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry. 1998;59(suppl 20):22-33.PubMedGoogle Scholar
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
Jaffe  AS, Krumholz  HM, Catellier  DJ,  et al.  Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study.  Am Heart J. 2006;152(1):126-135. doi:10.1016/j.ahj.2005.10.004PubMedGoogle ScholarCrossref
Killip  T  III, Kimball  JT.  Treatment of myocardial infarction in a coronary care unit: a two-year experience with 250 patients.  Am J Cardiol. 1967;20(4):457-464. doi:10.1016/0002-9149(67)90023-9PubMedGoogle ScholarCrossref
Criteria Committee of the New York Heart Association.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little Brown & Co; 1994:253-256.
Hamilton  M.  A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMedGoogle ScholarCrossref
Galløe  AM, Thuesen  L, Kelbaek  H,  et al.  Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial.  JAMA. 2008;299(4):409-416. doi:10.1001/jama.299.4.409PubMedGoogle ScholarCrossref
Jorge  RE, Robinson  RG, Arndt  S, Starkstein  S.  Mortality and poststroke depression: a placebo-controlled trial of antidepressants.  Am J Psychiatry. 2003;160(10):1823-1829. PubMedGoogle ScholarCrossref
Kim  JM, Bae  KY, Kang  HJ,  et al.  Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS.  Psychiatry Investig. 2014;11(1):89-94. PubMedGoogle ScholarCrossref
Kang  HJ, Stewart  R, Bae  KY,  et al.  Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: findings from the K-DEPACS and EsDEPACS studies.  Int J Cardiol. 2015;190:114-121. PubMedGoogle ScholarCrossref
Polyakova  M, Stuke  K, Schuemberg  K,  et al.  BDNF as a biomarker for successful treatment of mood disorders: a systematic and quantitative meta-analysis.  J Affect Disord. 2015;174:432-440. doi:10.1016/j.jad.2014.11.044PubMedGoogle ScholarCrossref
Rana  P, Sharma  AK, Jain  S,  et al.  Comparison of fluoxetine and 1-methyl-L-tryptophan in treatment of depression-like illness in bacillus Calmette-Guerin–induced inflammatory model of depression in mice.  J Basic Clin Physiol Pharmacol. 2016;27(6):569-576. doi:10.1515/jbcpp-2015-0120PubMedGoogle ScholarCrossref
Kemp  AH, Brunoni  AR, Santos  IS,  et al.  Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil Cohort baseline study.  Am J Psychiatry. 2014;171(12):1328-1334. PubMedGoogle ScholarCrossref
Dawood  T, Barton  DA, Lambert  EA,  et al.  Examining endothelial function and platelet reactivity in patients with depression before and after SSRI therapy.  Front Psychiatry. 2016;7:18. doi:10.3389/fpsyt.2016.00018PubMedGoogle ScholarCrossref
Bush  DE, Ziegelstein  RC, Tayback  M,  et al.  Even minimal symptoms of depression increase mortality risk after acute myocardial infarction.  Am J Cardiol. 2001;88(4):337-341. doi:10.1016/S0002-9149(01)01675-7PubMedGoogle ScholarCrossref
Yoon  J-S. Measuring ethnic differences in response to psychotropic drugs. In: Hindmarch  I, Stonier  PD, eds.  Human Psychopharmacology: Measures and Methods, Vol 5. Chichester, England: John Wiley & Sons Ltd; 1995:31-51.
Gottlieb  SS, Kop  WJ, Thomas  SA,  et al.  A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure.  Am Heart J. 2007;153(5):868-873. doi:10.1016/j.ahj.2007.02.024PubMedGoogle ScholarCrossref
O’Connor  CM, Jiang  W, Kuchibhatla  M,  et al.  Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.  J Am Coll Cardiol. 2010;56(9):692-699. PubMedGoogle ScholarCrossref
Angermann  CE, Gelbrich  G, Störk  S,  et al.  Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial.  JAMA. 2016;315(24):2683-2693. doi:10.1001/jama.2016.7635PubMedGoogle ScholarCrossref
Original Investigation
July 24/31, 2018

Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial

Author Affiliations
  • 1Department of Psychiatry, Chonnam National University Medical School, Republic of Korea
  • 2King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, England
  • 3South London and Maudsley NHS Foundation Trust, London, England
  • 4Department of Cardiology, Chonnam National University Medical School, Republic of Korea
JAMA. 2018;320(4):350-357. doi:10.1001/jama.2018.9422
Key Points

Question  Does antidepressant treatment of depression shortly after acute coronary syndrome improve long-term cardiac outcomes?

Findings  In this randomized clinical trial that included 300 patients with recent acute coronary syndrome and depression, 24-week treatment with escitalopram compared with placebo resulted in an occurrence of major adverse cardiac outcomes of 40.9% vs 53.6% after a median follow-up of 8.1 years, a difference that was statistically significant.

Meaning  Treatment with escitalopram for depression following recent acute coronary syndrome may improve long-term cardiac outcomes.


Importance  Depression has been associated with poorer medical outcomes in acute coronary syndrome (ACS), but there are few data on the effects of antidepressant treatment on long-term prognosis.

Objective  To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS.

Design, Setting, and Participants  Randomized, double-blind, placebo-controlled trial conducted among 300 patients with recent ACS and depression enrolled from May 2007 to March 2013, with follow-up completed in June 2017, at Chonnam National University Hospital, Gwangju, South Korea.

Interventions  Patients were randomly assigned to receive either escitalopram in flexible dosages of 5, 10, 15, or 20 mg/d (n = 149) or matched placebo (n = 151) for 24 weeks.

Main Outcomes and Measures  The primary outcome was MACE, a composite of all-cause mortality, myocardial infarction (MI), and percutaneous coronary intervention (PCI). Four secondary outcomes were the individual MACE components of all-cause mortality, cardiac death, MI, and PCI. Cox proportional hazards models were used to compare the escitalopram and placebo groups by time to first MACE.

Results  Among 300 randomized patients (mean age, 60 years; 119 women [39.3%]), 100% completed a median of 8.1 (interquartile range, 7.5-9.0) years of follow-up. MACE occurred in 61 patients (40.9%) receiving escitalopram and in 81 (53.6%) receiving placebo (hazard ratio [HR], 0.69; 95% CI, 0.49-0.96; P = .03). Comparing individual MACE outcomes between the escitalopram and placebo groups, respectively, incidences for all-cause mortality were 20.8% vs 24.5% (HR, 0.82; 95% CI, 0.51-1.33; P = .43), for cardiac death, 10.7% vs 13.2% (HR, 0.79; 95% CI, 0.41-1.52; P = .48); for MI, 8.7% vs 15.2% (HR, 0.54; 95% CI, 0.27-0.96; P = .04), and for PCI, 12.8% vs 19.9% (HR, 0.58; 95% CI, 0.33-1.04; P = .07).

Conclusions and Relevance  Among patients with depression following recent acute coronary syndrome, 24-week treatment with escitalopram compared with placebo resulted in a lower risk of major adverse cardiac events after a median of 8.1 years. Further research is needed to assess the generalizability of these findings.

Trial Registration  ClinicalTrials.gov Identifier: NCT00419471